Drug · CHEMBL9
NORFLOXACIN
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. NORFLOXACIN. Drugs and targets, record CHEMBL9. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL9
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
Targets0
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
None in this release.
Diseases7
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Disease | Open Targets' stage | Stage reported by | Reports | Of them trials | Its drugs |
|---|---|---|---|---|---|
| Hermansky-Pudlak syndrome | Phase 2 | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=MONDO_0019312 |
| acute cystitis | Phase 3 | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=MONDO_0001650 |
| cirrhosis of liver | Phase 3 | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=MONDO_0005155 |
| esophageal varices | Phase 3 | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=MONDO_0001221 |
| portal hypertension | Phase 3 | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=MONDO_0005080 |
| bacterial infectious disease | Approval | ATC and TTD | 2 | 0 | https://conductscience.org/library/drugs?q=MONDO_0005113 |
| eye infection | Approval | ATC | 1 | 0 | https://conductscience.org/library/drugs?q=EFO_1001888 |
Source Open Targets
Trials18
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT07436104 | Mortality Control Program for Economically Productive Age Group in Tribal Area of Melghat. | Phase 4 | 72,564 | norfloxacin | Its name | ClinicalTrials.gov | |
| NCT03506256 | Noroxin Efficacy and Safety Trial | Phase 4 | 1,000 | norfloxacin | Its name | ClinicalTrials.gov | |
| NCT04159870 | Rifaximin Versus Norfloxacin in Spontaneous Bacterial Peritonitis | Phase 3 | 322 | norfloxacin | Its name | ClinicalTrials.gov | |
| NCT01037959 | Norfloxacin Therapy for Patients With Cirrhosis and Severe Liver Failure | Phase 3 | 291 | norfloxacin | Its name | ClinicalTrials.gov | |
| NCT06199843 | Efficacy of Rifaximin vs Norfloxacin for Secondary Prophylaxis of SBP (NORRIF Trial) | 280 | norfloxacin | Its name | ClinicalTrials.gov | ||
| NCT01039545 | Symptomatic Therapy of Uncomplicated Lower Urinary Tract Infections in the Ambulatory Setting. | Phase 4 | 253 | norfloxacin | Its name | ClinicalTrials.gov | |
| NCT03695705 | Rifaximin and Norfloxacin for Prevention of SBP in Adults With Decompensated Cirrhosis | Phase 3 | 142 | norfloxacin | Its name | ClinicalTrials.gov | |
| NCT01542801 | Norfloxacin Versus Ciprofloxacin for Spontaneous Bacterial Peritonitis (SBP) Prevention | Phase 4 | 124 | norfloxacin | Its name | ClinicalTrials.gov | |
| NCT03702426 | Comparison of the Efficacy of Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) and Norfloxacin in Secondary Prophylaxis for Spontaneous Bacterial Peritonitis | 120 | norfloxacin | Its name | ClinicalTrials.gov | ||
| NCT00947336 | Evaluation of Safety & Efficacy of Synbiotic on the Incidence and Recurrence of Spontaneous Bacterial Peritonitis (SBP) in Cirrhotics | Phase 3 | 110 | norfloxacin | Its name | ClinicalTrials.gov |
1 to 10 of 18
See all 18 trialsComparisons in its trials0
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
None in this release.
Papers from its trials17
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials0
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
None in this release.
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL9
GET https://conductscience.org/api/drugs/v1/CHEMBL9/targets